A chemical engineering perspective of nanoparticle‐based targeted drug delivery: A unit process approach

Anselmo, Aaron C.; Mitragotri, Samir

doi:10.1002/aic.15189

Cited by 8 publications

(4 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Methods to predict nanoparticle performance (e.g., computational or theoretical modeling) can be leveraged to better predict clinical trial results. Combining these techniques with experimental results and devices designed to mimic physiological tissues and conditions (e.g., organs‐on‐chips) may one day improve nanoparticle predictions of efficacy and performance . Unfortunately, this remains a challenge even at the preclinical level where relevant estimates are typically generated from compartmental analyses or pharmacokinetic models .…”

Section: The Main Challengesmentioning

confidence: 99%

“…91 devices designed to mimic physiological tissues and conditions (e.g., organs-on-chips) may one day improve nanoparticle predictions of efficacy and performance. 129 Unfortunately, this remains a challenge even at the preclinical level where relevant estimates are typically generated from compartmental analyses or pharmacokinetic models. 130 As discussed above, correlation between human and animal data is essential.…”

Section: Heterogeneity Of Human Disease and Relevant Animal Modelsmentioning

confidence: 99%

See 1 more Smart Citation

Nanoparticles in the clinic

Anselmo

Mitragotri

2016

Bioengineering & Transla Med

Self Cite

1,116

603

View full text Add to dashboard Cite

Nanoparticle/microparticle‐based drug delivery systems for systemic (i.e., intravenous) applications have significant advantages over their nonformulated and free drug counterparts. For example, nanoparticle systems are capable of delivering therapeutics and treating areas of the body that other delivery systems cannot reach. As such, nanoparticle drug delivery and imaging systems are one of the most investigated systems in preclinical and clinical settings. Here, we will highlight the diversity of nanoparticle types, the key advantages these systems have over their free drug counterparts, and discuss their overall potential in influencing clinical care. In particular, we will focus on current clinical trials for nanoparticle formulations that have yet to be clinically approved. Additional emphasis will be on clinically approved nanoparticle systems, both for their currently approved indications and their use in active clinical trials. Finally, we will discuss many of the often overlooked biological, technological, and study design challenges that impact the clinical success of nanoparticle delivery systems.

show abstract

Section: The Main Challengesmentioning

confidence: 99%

Section: Heterogeneity Of Human Disease and Relevant Animal Modelsmentioning

confidence: 99%

Nanoparticles in the clinic

Anselmo

Mitragotri

2016

Bioengineering & Transla Med

Self Cite

1,116

603

View full text Add to dashboard Cite

show abstract

“…In recent years, chemical engineers are also playing an increasing role in establishing enabling areas such as laboratory automation, advanced controls and informatics to collect, analyze, and interpret an immense amount of insightful process data that would otherwise be inaccessible. In addition to developing processes for active pharmaceutical ingredients and drug products, chemical engineers have made significant contributions in developing novel drug delivery approaches 9–12 Over the last decade, pharma companies have also come together to form several precompetitive collaborations to enable sharing of experiences in the precompetitive space, benchmarking with peers, joint investment in technology development and collectively influence regulatory thinking. The International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) and the Enabling Technologies Consortium™ (ETC) are two such precompetitive collaborations with a significant number of member companies 13,14 Additionally, the industry has continued to sponsor academic research in key areas of future need.…”

Section: Introductionmentioning

confidence: 99%

Positioning for a sustainable future—Role of chemical engineers in transforming pharmaceutical process development

2021

View full text Add to dashboard Cite

“…It requires deep knowledge about how atherosclerosis impairs the function of a coronary artery network. Nanoparticle-based diagnosis and drug delivery may be ameliorated by encompassing state of the art chemical engineering know-how [13][14][15] . For example, nanoparticles could be applied as drug carriers to mediate the underlying hemodynamics in a stenotic vascular channel [16][17][18][19][20] .…”

Section: Introductionmentioning

confidence: 99%

Synchronous screening-and-optimization of nano-engineered blood pressure-drop using rapid robust non-linear Taguchi profiling

Besseris

2019

Chemical Engineering Science

View full text Add to dashboard Cite

Atherosclerosis induces abnormal blood-flow patterns in coronary arteries mainly because of the irregular accumulation of fibrofatty plaque on the artery walls. Morphological alterations of the wall-surface attributes downgrade vascular elasticity, which compromises the normal blood-pressure gradient behavior by sporadically interfering with the effective-flow crosssection adjustment. An iron-oxide booster has been recently studied as a potential nanoparticle treatment to regulate an elevated blood-pressure condition. Taguchi-type multifactorial experimentation rapidly generates small and dense datasets in order to expedite arterial flow screening/optimization predictions. The optimal blood pressure-drop performance is investigated against four vital controlling factors. We show that tracking down inherently complex blood-flow phenomena often entails the elucidation of non-linear and messy data structures. Translating such data demands robust and agile techniques to decipher governing relationships while guarding against spurious effects from uncertainty asymmetry. We also show that by using distribution-free profiling, we may synchronously accomplish the screening and optimization tasks more accurately in comparison to other competing techniques. Illustrating our technique on a chemical engineering paradigm, we found that out of the four investigated factors only the blood behavior index to be strongly influential. A blood behavior index setting of 0.5, which is below the normal physiological limit, minimizes the blood pressure drop at an optimal value of 385 Pa/m. The proposed methodology demonstrates how the required sampling size may be further reduced, thus making the study even more economically 3 and practically efficient. This was shown to be achieved without relinquishing important information about the dominant phenomena, hence rendering our solution to be also lean and agile.

show abstract

A chemical engineering perspective of nanoparticle‐based targeted drug delivery: A unit process approach

Cited by 8 publications

References 46 publications

Nanoparticles in the clinic

Nanoparticles in the clinic

Positioning for a sustainable future—Role of chemical engineers in transforming pharmaceutical process development

Synchronous screening-and-optimization of nano-engineered blood pressure-drop using rapid robust non-linear Taguchi profiling

Contact Info

Product

Resources

About